Literature DB >> 27186889

Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review.

C M Nijenhuis1, J H M Schellens2,3, J H Beijnen1,3.   

Abstract

Human radiolabeled mass balance studies are performed to obtain information about the absorption, distribution, metabolism, and excretion of a drug in development. The main goals are to determine the route of elimination and major metabolic pathways. This review provides an overview of the current regulatory guidelines concerning human radiolabeled mass balance studies and discusses scientific trends seen in the last decade with a focus on mass balance studies of anticancer drugs. This paper also provides an overview of mass balance studies of anticancer agents that were executed in the last 10 years.

Entities:  

Keywords:  Metabolite identification; carbon-14; mass balance studies; pharmacokinetics; radiolabeled drugs; regulatory guidelines; study design

Mesh:

Substances:

Year:  2016        PMID: 27186889     DOI: 10.1080/03602532.2016.1181081

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  8 in total

1.  Pharmacokinetics and excretion of 14C-Plitidepsin in patients with advanced cancer.

Authors:  L van Andel; S Fudio; H Rosing; S Munt; B Miguel-Lillo; I González; M M Tibben; N de Vries; A H M de Vries Schultink; J H M Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2017-01-23       Impact factor: 3.850

2.  Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects.

Authors:  Zhi-Yi Zhang; Jing Wang; Vikram Kansra; Xiaodong Wang
Journal:  Invest New Drugs       Date:  2018-07-21       Impact factor: 3.850

3.  Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer.

Authors:  Lotte van Andel; Z Zhang; S Lu; V Kansra; S Agarwal; L Hughes; M M Tibben; A Gebretensae; L Lucas; M J X Hillebrand; H Rosing; J H M Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2017-03-16       Impact factor: 3.850

Review 4.  Combining Isotopic Tracer Techniques to Increase Efficiency of Clinical Pharmacokinetic Trials in Oncology.

Authors:  Jeroen Roosendaal; Hilde Rosing; Jos H Beijnen
Journal:  Drugs R D       Date:  2020-06

5.  An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data.

Authors:  Alexander D James; Hilmar Schiller; Cyrille Marvalin; Yi Jin; Hubert Borell; Ad F Roffel; Ulrike Glaenzel; Yan Ji; Gian Camenisch
Journal:  Pharmacol Res Perspect       Date:  2020-06

Review 6.  The Importance of the Human Mass Balance Study in Regulatory Submissions.

Authors:  Paola Coppola; Anita Andersson; Susan Cole
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-10-25

Review 7.  Late-Stage Carbon-14 Labeling and Isotope Exchange: Emerging Opportunities and Future Challenges.

Authors:  Victor Babin; Frédéric Taran; Davide Audisio
Journal:  JACS Au       Date:  2022-06-07

Review 8.  Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment.

Authors:  Lotte van Andel; Hilde Rosing; Jan Hm Schellens; Jos H Beijnen
Journal:  Mar Drugs       Date:  2018-07-23       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.